Objective 1 (IVI): Apply the established strategy to attenuate high pathogenic PEDV strains and generate three attenuated vaccine candidates.
Objective 2 (IVI): Generate the attenuated PEDV vaccine candidates by reverse genetics and production of virus stocks for in vivo assessment
Objective 3 (BI): Assessment of attenuation and immunogenicity of PEDV vaccine candidates